Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02260388 · ClinicalTrials.gov registry record · Phase 4
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations
A Phase 4 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 402
- Enrollment target
NCT02260388 is a Phase 4 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 402 participants.
The verdict
NCT02260388, a Phase 4 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 402 participants
- Enrollment target
Study Summary
The purpose of this large comparative effectiveness study led by Richard J. Barohn, MD, of the University of Kansas Medical Center, is to learn about the safety and effectiveness of nortriptyline, duloxetine, pregabalin and mexiletine in treating cryptogenic sensory polyneuropathy (CSPN).
Interventions
- DRUG Duloxetine
- DRUG Pregabalin
- DRUG Nortriptyline
- DRUG Mexiletine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2014-10 |
| Est. Completion | 2017-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02260388
The ClinicalTrials.gov registry entry for NCT02260388 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Duloxetine is the first listed.
NCT02260388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02260388 about?
NCT02260388 is a clinical study titled "Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations". The purpose of this large comparative effectiveness study led by Richard J. Barohn, MD, of the University of Kansas Medical Center, is to learn about the safety and effectiveness of nortriptyline, duloxetine, pregabalin and mexiletine in treating cryptogenic sensory polyneuropathy (CSPN).
What is the current status of trial NCT02260388?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 402 participants. The study started on 2014-10. Estimated completion is 2017-09.
What interventions are being tested in trial NCT02260388?
The interventions under investigation include: Duloxetine (DRUG), Pregabalin (DRUG), Nortriptyline (DRUG), Mexiletine (DRUG).
Who is sponsoring clinical trial NCT02260388?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.